Should you buy Regeneron Pharmaceuticals stock now?
The technical signal for Regeneron Pharmaceuticals is currently Hold. Regeneron Pharmaceuticals trades at $737.98 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -14.646 with falling momentum (signal: -7.395); RSI is at 38.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $853.19 points to 15.6% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Regeneron Pharmaceuticals stock?
The average analyst price target for Regeneron Pharmaceuticals is $853.19. The current price is $737.98, which gives an upside of 15.6%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $767.87 and $938.51.
Is Regeneron Pharmaceuticals a dividend stock?
Yes, Regeneron Pharmaceuticals is a dividend stock with a dividend yield of 0.50%. The latest dividend was $0.94 per share. The latest ex-dividend date (traded without the dividend) was Aug 18, 2026. The payout ratio is 8.2%, which is considered sustainable.
When does Regeneron Pharmaceuticals pay a dividend in 2026?
The next dividend date for Regeneron Pharmaceuticals has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Aug 18, 2026. The latest dividend was $0.94 per share with an ex-dividend date of Aug 18, 2026. The dividend yield is 0.50%. The payout ratio of 8.2% points to a sustainable dividend with room to grow.
What is the risk of Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals is rated as a stock in the risk category Balanced. the annual standard deviation is 32.9%, which classifies the stock as Balanced.
Is Regeneron Pharmaceuticals overvalued?
No, Regeneron Pharmaceuticals is considered undervalued based on the analyst price target (15.6% upside). Regeneron Pharmaceuticals has the following valuation ratios: a P/E ratio of 18.0 (moderately valued), a P/S ratio of 4.8, a P/B ratio of 2.6. The analyst price target suggests that the stock is undervalued by 15.6%.
Is Regeneron Pharmaceuticals overbought?
No, Regeneron Pharmaceuticals is not overbought. RSI is at 38.3 (neutral zone). The technical indicators show: RSI is at 38.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.7% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Regeneron Pharmaceuticals earnings report?
Regeneron Pharmaceuticals reports its next earnings on October 30, 2026. The stock currently trades at $737.98. With a P/E ratio of 18.0, the market will be watching closely whether earnings meet expectations.
Is Regeneron Pharmaceuticals shorted?
Yes, Regeneron Pharmaceuticals is shorted with 2.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Regeneron Pharmaceuticals stock?
No, insiders are not buying Regeneron Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 5 sales. On a net basis, 3,302,458 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 11,997,162 $ sold. Active sellers include McCourt Marion, Guarini Kathryn, Zoghbi Huda Y and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Regeneron Pharmaceuticals a good stock?
Based on our total score, Regeneron Pharmaceuticals is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 60/100, Quality: 79/100, Momentum: 60/100. In addition: analysts see 15.6% upside to the price target; a dividend of 0.50%; technical signal: Hold. Whether Regeneron Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Regeneron Pharmaceuticals stock?
The outlook for Regeneron Pharmaceuticals based on current data: the average analyst price target is $853.19 (+15.6%); the next earnings report is due on Oct 30, 2026, which can move the price; the P/E ratio is 18.0 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Regeneron Pharmaceuticals stock falling?
Regeneron Pharmaceuticals is falling right now. The technical indicators show: the price is 4.7% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Regeneron Pharmaceuticals go?
The average analyst price target for Regeneron Pharmaceuticals is $853.19, which corresponds to a potential gain of 15.6% from the current price of $737.98. The stock has traded between $538.24 and $859.34 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Regeneron Pharmaceuticals fall?
The stock has traded as low as $538.24 over the last 52 weeks — that is 27.1% below the current price of $737.98. The biggest decline (drawdown) in the same period was 37.4% from high to low. Within a year, the price typically swings about ±32.9% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Regeneron Pharmaceuticals do?
Regeneron is a large pharmaceutical company. It discovers, develops and sells medicines for various diseases around the world. It makes most of its money by selling its own medicines.
The company is especially known for two products. Eylea is an eye medicine that treats eye d... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Regeneron Pharmaceuticals as an investment.
Did Regeneron Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Regeneron Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Regeneron Pharmaceuticals making money or losing money?
Yes, Regeneron Pharmaceuticals is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 27.9% — which is excellent. The operating margin (profit before interest and taxes) is 33.1%. At a P/E ratio of 18.0, you currently pay 18.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Regeneron Pharmaceuticals go bankrupt?
The bankruptcy risk of Regeneron Pharmaceuticals is rated as low. Altman Z2 (a model for assessing financial distress) is 9.13 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 29% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Regeneron Pharmaceuticals have a lot of debt?
No, Regeneron Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 29%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Regeneron Pharmaceuticals service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 139.9x, and the company has more cash than debt (net cash).
